ATH 33.3% 0.4¢ alterity therapeutics limited

After the US orphan drug decision for PBT434 in Jan:...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,840 Posts.
    lightbulb Created with Sketch. 995
    After the US orphan drug decision for PBT434 in Jan: "Significant market potential for MSA alone – estimated peak sales of US$750M ". This was only for the US and now we have Europe with 500M people. So perhaps we can now talk about the $1.5B - 2 B peak sales for PBT434 in MSA alone. But we need good results in phase II.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.